Patent · US Expired

Recombinant retroviruses expressing a protein that converts a pro-drug into a cytotoxic agent

US5691177A · kind A · utility

47Cited by
16References
24Claims
0Family size

Inventors

Key dates

Filing dateJun 5, 1995
Grant dateNov 25, 1997
Priority date
Expiry dateJun 5, 2015

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2740/16222
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.